Stay updated on Dolutegravir Plus NRTIs in HIV-2 Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page.

Latest updates to the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page
- Check3 days agoChange DetectedThe displayed site revision updates from v3.8.0 to v3.8.1, with no change to the clinical trial record.SummaryDifference0.1%

- Check10 days agoChange DetectedThe clinical trial record for dolutegravir plus two NRTIs in treatment-naïve people with HIV-2 is now displayed, including study design, participation criteria, locations, and outcome measures.SummaryDifference42%

- Check17 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedA site-wide NIH transition notice appears above the unchanged 403 Forbidden page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe 403 Forbidden page’s footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedA 403 Forbidden error page is now displayed, replacing the study details with a simple error message and a Home link.SummaryDifference17%

Stay in the know with updates to Dolutegravir Plus NRTIs in HIV-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir Plus NRTIs in HIV-2 Clinical Trial page.